Abstract
The fundamental inaccessibility of the human neural cell types affected by neurological disorders prevents their isolation for in vitro studies of disease mechanisms or for drug screening efforts. Pluripotent stem cells represent a new interesting way to generate models of human neurological disorders, explore the physiopathological mechanisms and develop new therapeutic strategies. Disease-specific human embryonic stem cells were the first source of material to be used to study certain disease states. The recent demonstration that human somatic cells, such as fibroblasts or blood cells, can be genetically converted to induced pluripotent stem cells (hiPSCs) together with the continuous improvement of methods to differentiate these cells into disease-affected neuronal subtypes opens new perspectives to model and understand a large number of human pathologies. This review focuses on the opportunities concerning the use disease-specific human pluripotent stem cells as well as the different challenges that still need to be overcome. We also discuss the recent improvements in the genetic manipulation of human pluripotent stem cells and the consequences of these on disease modeling and drug screening for neurological diseases.
Keywords: Human induced pluripotent stem cells, human embryonic stem cells, genetic diseases, disease modeling, drug screening
Current Gene Therapy
Title:Genetically-Modified Human Pluripotent Stem Cells: New Hopes for the Understanding and the Treatment of Neurological Diseases?
Volume: 13 Issue: 2
Author(s): Stephane Nedelec, Brigitte Onteniente, Marc Peschanski and Cecile Martinat
Affiliation:
Keywords: Human induced pluripotent stem cells, human embryonic stem cells, genetic diseases, disease modeling, drug screening
Abstract: The fundamental inaccessibility of the human neural cell types affected by neurological disorders prevents their isolation for in vitro studies of disease mechanisms or for drug screening efforts. Pluripotent stem cells represent a new interesting way to generate models of human neurological disorders, explore the physiopathological mechanisms and develop new therapeutic strategies. Disease-specific human embryonic stem cells were the first source of material to be used to study certain disease states. The recent demonstration that human somatic cells, such as fibroblasts or blood cells, can be genetically converted to induced pluripotent stem cells (hiPSCs) together with the continuous improvement of methods to differentiate these cells into disease-affected neuronal subtypes opens new perspectives to model and understand a large number of human pathologies. This review focuses on the opportunities concerning the use disease-specific human pluripotent stem cells as well as the different challenges that still need to be overcome. We also discuss the recent improvements in the genetic manipulation of human pluripotent stem cells and the consequences of these on disease modeling and drug screening for neurological diseases.
Export Options
About this article
Cite this article as:
Nedelec Stephane, Onteniente Brigitte, Peschanski Marc and Martinat Cecile, Genetically-Modified Human Pluripotent Stem Cells: New Hopes for the Understanding and the Treatment of Neurological Diseases?, Current Gene Therapy 2013; 13 (2) . https://dx.doi.org/10.2174/1566523211313020005
DOI https://dx.doi.org/10.2174/1566523211313020005 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
SLC1 Glutamate Transporters and Diseases: Psychiatric Diseases and Pathological Pain
Current Molecular Pharmacology Inflammation: Beneficial or Detrimental After Spinal Cord Injury?
Recent Patents on CNS Drug Discovery (Discontinued) Retraction Notice: Potential Application of Venom Proteins in Designing of Medicines for Treating Human Neurodegenerative Disorders
Protein & Peptide Letters The Antioxidant Response as a Drug Target in Diabetic Neuropathy
Current Drug Targets Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?
Current Neuropharmacology Current Update on Synopsis of miRNA Dysregulation in Neurological Disorders
CNS & Neurological Disorders - Drug Targets YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer’s Disease
Current Neuropharmacology Neurotrophic Factor Treatment After Spinal Root Avulsion Injury
Central Nervous System Agents in Medicinal Chemistry Position Based Nucleotide Analysis of miR168 Family in Higher Plants and its Targets in Mammalian Transcripts
MicroRNA Roles of TRAF6 in Central Nervous System
Current Neuropharmacology Small Molecules in Stem Cell Research
Current Pharmaceutical Biotechnology Role of Environmental Contaminants in the Etiology of Alzheimer’s Disease: A Review
Current Alzheimer Research Catatonia Due to a General Medical Condition (Organic Catatonia)
Current Psychiatry Reviews Proteomic Approaches Contributing to the Understanding of Neurodegenerative Diseases: Focus on Alzheimers Disease
Current Proteomics Parkinson's Disease: From Genetics to Clinical Practice
Current Genomics Meet Our Editorial Board Member
Recent Patents on CNS Drug Discovery (Discontinued) Preface [Hot topic: Potential Therapeutic Agents for Parkinsons Disease (Executive Editor: Masato Asanuma)]
Current Pharmaceutical Design From Bone to Brain: Human Skeletal Stem Cell Therapy for Stroke
Central Nervous System Agents in Medicinal Chemistry Inflammatory Process in Alzheimer’s and Parkinson's Diseases: Central Role of Cytokines
Current Pharmaceutical Design Designing Multi-Targeted Therapeutics for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry